Guggenheim Sets $8 Price Target as Black Diamond Therapeutics, Inc. (BDTX) Prepares Phase 2 Results
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is among the best stocks with the highest upside potential. Guggenheim assumed coverage on Black Diamond Therapeutics, Inc.








